Yahoo Finance

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
PR Newswire

Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

AMSTERDAM and SEONGNAM-SI, South Korea , Sept. 25, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the ...
Yahoo Finance

CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC Therapies

HOUSTON, November 04, 2024--(BUSINESS WIRE)--CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing ...
Finanznachrichten

Innovent Biologics: Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
조선일보

Idience and Aptis collaborate to develop next-generation dual payload ADC cancer drug

Idience, a cancer drug development company of Ildong Pharmaceutical Group, announced on the 12th that it has signed a joint development agreement with Aptis, a subsidiary of Dong-A Socio Group ...